Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · IEX Real-Time Price · USD
1.86 0.00 (0.00%)
Oct 25, 2021 4:00 PM EDT - Market closed
Income Statement (Annual)
Financials in millions USD. Fiscal year is January - December.
| Year | 2020 | 2019 | 2018 |
|---|---|---|---|
| Revenue | 0.7 | 1.12 | 4.04 |
| Revenue Growth | -37.79% | -72.22% | - |
| Gross Profit | 0.7 | 1.12 | 4.04 |
| Selling, General & Admin | 2.62 | 4.27 | 2.52 |
| Research & Development | 0.89 | 2.55 | 3.65 |
| Operating Expenses | 3.52 | 6.82 | 6.16 |
| Operating Income | -2.82 | -5.7 | -2.12 |
| Interest Expense / Income | 0.03 | 0.02 | 0.03 |
| Pretax Income | -2.85 | -5.72 | -2.15 |
| Net Income | -2.85 | -5.72 | -2.15 |
| Net Income Common | -2.85 | -5.72 | -2.15 |
| Shares Outstanding (Basic) | 8 | 8 | 8 |
| Shares Outstanding (Diluted) | 8 | 8 | 8 |
| Shares Change | 0.39% | 2.08% | - |
| EPS (Basic) | -0.35 | -0.70 | -0.27 |
| EPS (Diluted) | -0.35 | -0.70 | -0.27 |
| Free Cash Flow Per Share | -0.14 | -0.04 | 0.09 |
| Gross Margin | 100.00% | 100.00% | 100.00% |
| Operating Margin | -403.52% | -507.52% | -52.52% |
| Profit Margin | -407.73% | -509.73% | -53.27% |
| Free Cash Flow Margin | -161.69% | -30.13% | 17.69% |
| EBITDA | -2.82 | -5.7 | -2.12 |
| EBITDA Margin | -403.52% | -507.52% | -52.52% |
| EBIT | -2.82 | -5.7 | -2.12 |
| EBIT Margin | -403.52% | -507.52% | -52.52% |
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).